Saturday 17 October 2026
Export ANRO’s income statement to Excel — free account
Alto Neuroscience, Inc.
ANRO Healthcare Biotechnology
In the quarter to June 2026, EPS was flat, free cash flow fell 43.4% and total debt fell 15.7%, each against the same quarter a year earlier.
22.07
0.55
−2.43%
Follow ANRO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (49.17%) | (38.86%) | (41.80%) | (45.01%) |
+8 more TTM periods Free account |
|
| (40.90%) | (33.16%) | (34.92%) | (36.77%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(36.20%) | (28.77%) | (37.58%) | (47.01%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.61) | (1.91) | (1.80) | (1.99) | |
Free Cash Flow |
(68.84) | (62.86) | (51.79) | (53.80) | |
Capital Expenditures |
(0.56) | (0.56) | (0.02) | (0.53) | |
| Other line items | |||||
Cash ROIC |
(14.29%) | (11.96%) | (14.94%) | (19.79%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(39.04) | (32.21) | (26.88) | (29.77) | |
Operating CF/Net income |
0.81 | 0.84 | 0.82 | 0.86 | |
Depreciation/Fixed assets |
0.34 | 0.30 | 0.35 | 0.33 | |
Capex/Depreciation |
(0.81) | (0.82) | (0.04) | (0.79) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.59) | (1.89) | (1.79) | (1.97) | |
Capex per Share |
(0.01) | (0.02) | 0.00 | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates